Literature DB >> 16738488

CREB-binding protein activation by presenilin 1 but not by its M146L mutant.

Yitshak I Francis1, Anastasis Stephanou, David S Latchman.   

Abstract

The transcriptional coactivator CREB-binding protein plays a key role in regulating gene expression in a number of different cell types. Recently, a report has suggested a link between CREB-binding protein and presenilins, which are mutated in many cases of early onset Alzheimer's disease. Thus, presenilin 1 and 2 double knockout mice showed reductions in CREB-binding protein levels and in cAMP response element-dependent gene expression in the cerebral cortex, which is likely to contribute to the subsequent neuronal degeneration. This suggests that the inactivation of CREB-binding protein caused by mutation in presenilin 1 may be involved in the disease process. We have shown that wild-type presenilin 1 stimulates the transcriptional activity ability of CREB-binding protein whereas presenilin 1 M146L mutant did not produce such an effect. The activation of CREB-binding protein by wild-type presenilin 1 involves the PI 3-kinase, p38 mitogen-activated protein kinase (MAPK) and p42/p44 MAPK pathways and targets primarily the C terminus of CREB-binding protein. To our knowledge, this is the first report that shows regulation of CREB-binding protein activity by wild-type presenilin 1 and not by its M146L mutant, and suggests a mechanism in which mutation of presenilin 1 may lead to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738488     DOI: 10.1097/01.wnr.0000220137.06542.a0

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  11 in total

Review 1.  The role of histone acetylation in memory formation and cognitive impairments.

Authors:  Lucia Peixoto; Ted Abel
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Diminished CRE-Induced Plasticity is Linked to Memory Deficits in Familial Alzheimer's Disease Mice.

Authors:  Nancy Bartolotti; Laura Segura; Orly Lazarov
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 3.  Acetyltransferases (HATs) as targets for neurological therapeutics.

Authors:  Anne Schneider; Snehajyoti Chatterjee; Olivier Bousiges; B Ruthrotha Selvi; Amrutha Swaminathan; Raphaelle Cassel; Frédéric Blanc; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

4.  Is CREB the angry bird that releases memory in Alzheimer's?

Authors:  Allan Wang; James A Bibb
Journal:  Neuropsychopharmacology       Date:  2011-10       Impact factor: 7.853

Review 5.  Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Authors:  Andrew F Teich; Ottavio Arancio
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

6.  CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease.

Authors:  Antonella Caccamo; Monica A Maldonado; Alex F Bokov; Smita Majumder; Salvatore Oddo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

Review 7.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

8.  Presenilins regulate neurotrypsin gene expression and neurotrypsin-dependent agrin cleavage via cyclic AMP response element-binding protein (CREB) modulation.

Authors:  Angels Almenar-Queralt; Sonia N Kim; Christopher Benner; Cheryl M Herrera; David E Kang; Ivan Garcia-Bassets; Lawrence S B Goldstein
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

9.  Reduced pCREB in Alzheimer's disease prefrontal cortex is reflected in peripheral blood mononuclear cells.

Authors:  N Bartolotti; D A Bennett; O Lazarov
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

Review 10.  Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.

Authors:  Luis M Valor; Jose Viosca; Jose P Lopez-Atalaya; Angel Barco
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.